Related Experiment Video
Updated: Nov 11, 2025

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Assessing the impact of COVID-19 on registered interventional clinical trials
1Department of Public Health Science, Division of Biostatistics & Bioinformatics, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Abstract:
The coronavirus disease 2019 (COVID-19) pandemic has led to a dramatic impact worldwide and presented unprecedented challenges for clinical and translational medicine. We assess the impact of COVID-19 on submitted and completed interventional clinical trials that have been registered on ClinicalTrials.gov. After classifying over 85% of the registered clinical trials by their source, we carefully model the number of submitted and completed trials before and after March 2020. Overall, we find minimal impact of COVID-19 on the number of submitted clinical trials, although a much more substantial impact is observed for completed clinical trials. We also show that clinical trials with a pharmaceutical sponsor were more successful at completing trials during the pandemic compared to the trials with academic/hospital/government sponsors.
More Related Videos
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Therapeutic Drug Monitoring: Affecting Factors
Preclinical Development: Overview
Blinding

